<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74029">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02120443</url>
  </required_header>
  <id_info>
    <org_study_id>IVW400CS-05</org_study_id>
    <nct_id>NCT02120443</nct_id>
  </id_info>
  <brief_title>ivWatch Model 400: Device Validation for Non-Infiltrated Tissues</brief_title>
  <official_title>ivWatch Model 400: Device Validation for Non-Infiltrated Tissues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ivWatch, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ivWatch, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized study of 40 adult volunteers to assess the safety and efficacy of the ivWatch
      Model 400 when observing non-infiltrated (normal) tissues at common peripheral IV therapy
      sites.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>False Red Notification Rate</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>A measure for how often false red notifications are issued for subjects with normal (non-infiltrated) tissue.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>False Yellow Notification Rate</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>A measure for how often false yellow notifications are issued for subjects with normal (non-infiltrated) tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant Skin Irritation or Disruption to Skin Integrity</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of IV sites with significant skin irritation or disruption to skin integrity assessed at the end of the study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Infiltration of Peripheral IV Therapy</condition>
  <arm_group>
    <arm_group_label>Non-Infiltrated Tissue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ivWatch Model 400 monitored a common peripheral IV site over a 24 hour observation period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ivWatch Model 400</intervention_name>
    <description>The ivWatch Model 400 monitored tissue at common IV sites over a 24 hour period.</description>
    <arm_group_label>Non-Infiltrated Tissue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Pass health screen

          -  18 years or older

        Exclusion Criteria:

          -  Fail health screen
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ivWatch, LLC</name>
      <address>
        <city>Williamsburg</city>
        <state>Virginia</state>
        <zip>23185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>April 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ivWatch, LLC</investigator_affiliation>
    <investigator_full_name>Garret Bonnema</investigator_full_name>
    <investigator_title>Chief Science Officer</investigator_title>
  </responsible_party>
  <keyword>infiltration</keyword>
  <keyword>extravasation</keyword>
  <keyword>peripheral intravenous therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
